Free Trial

Prothena (PRTA) Competitors

Prothena logo
$8.21 -0.22 (-2.61%)
Closing price 04:00 PM Eastern
Extended Trading
$8.22 +0.01 (+0.12%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PRTA vs. APGE, CDTX, BEAM, BHVN, TWST, IMCR, AUPH, TVTX, ARDX, and WVE

Should you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Apogee Therapeutics (APGE), Cidara Therapeutics (CDTX), Beam Therapeutics (BEAM), Biohaven (BHVN), Twist Bioscience (TWST), Immunocore (IMCR), Aurinia Pharmaceuticals (AUPH), Travere Therapeutics (TVTX), Ardelyx (ARDX), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.

Prothena vs. Its Competitors

Prothena (NASDAQ:PRTA) and Apogee Therapeutics (NASDAQ:APGE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Prothena has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$10.34M42.74-$122.31M-$5.64-1.46
Apogee TherapeuticsN/AN/A-$182.15M-$4.13-8.93

Prothena has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.

Prothena presently has a consensus price target of $19.75, suggesting a potential upside of 140.56%. Apogee Therapeutics has a consensus price target of $97.29, suggesting a potential upside of 163.79%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Apogee Therapeutics is more favorable than Prothena.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prothena
1 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33
Apogee Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.88

Apogee Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -2,929.30%. Apogee Therapeutics' return on equity of -34.65% beat Prothena's return on equity.

Company Net Margins Return on Equity Return on Assets
Prothena-2,929.30% -62.17% -54.43%
Apogee Therapeutics N/A -34.65%-32.76%

In the previous week, Apogee Therapeutics had 10 more articles in the media than Prothena. MarketBeat recorded 13 mentions for Apogee Therapeutics and 3 mentions for Prothena. Apogee Therapeutics' average media sentiment score of 1.21 beat Prothena's score of 0.90 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prothena
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Apogee Therapeutics
8 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

97.1% of Prothena shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 9.2% of Prothena shares are held by company insiders. Comparatively, 42.8% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Apogee Therapeutics beats Prothena on 11 of the 15 factors compared between the two stocks.

Get Prothena News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRTA vs. The Competition

MetricProthenaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$441.94M$3.14B$5.81B$10.16B
Dividend YieldN/A2.32%5.69%4.60%
P/E Ratio-1.4621.3674.6225.97
Price / Sales42.74257.18454.4485.61
Price / CashN/A45.3337.0859.91
Price / Book0.919.6112.156.29
Net Income-$122.31M-$53.29M$3.28B$270.77M
7 Day Performance-3.98%0.36%0.98%3.32%
1 Month Performance8.89%8.98%7.19%6.40%
1 Year Performance-60.38%13.18%63.14%28.24%

Prothena Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRTA
Prothena
3.3013 of 5 stars
$8.21
-2.6%
$19.75
+140.6%
-59.7%$441.94M$10.34M-1.46130News Coverage
APGE
Apogee Therapeutics
2.9176 of 5 stars
$36.37
-0.7%
$97.29
+167.5%
-26.4%$1.68BN/A-8.8191News Coverage
Positive News
CDTX
Cidara Therapeutics
3.2774 of 5 stars
$65.39
+0.2%
$64.14
-1.9%
+458.3%$1.66B$1.27M-5.8890Positive News
BEAM
Beam Therapeutics
2.861 of 5 stars
$16.36
-2.9%
$48.45
+196.2%
-10.7%$1.66B$63.52M-3.64510
BHVN
Biohaven
3.2692 of 5 stars
$15.35
-1.1%
$54.23
+253.2%
-60.4%$1.63BN/A-2.00239Trending News
Gap Down
TWST
Twist Bioscience
3.987 of 5 stars
$26.97
+1.4%
$49.40
+83.2%
-42.3%$1.63B$312.97M-18.60990News Coverage
IMCR
Immunocore
1.859 of 5 stars
$32.22
-0.1%
$56.89
+76.6%
+10.9%$1.62B$310.20M-80.55320
AUPH
Aurinia Pharmaceuticals
2.9714 of 5 stars
$11.99
-0.7%
$12.00
+0.1%
+95.7%$1.58B$235.13M27.88300News Coverage
Positive News
TVTX
Travere Therapeutics
2.983 of 5 stars
$17.50
-1.1%
$33.43
+91.0%
+104.2%$1.56B$233.18M-8.58460News Coverage
Analyst Forecast
ARDX
Ardelyx
4.6258 of 5 stars
$6.36
-0.3%
$11.50
+80.8%
+12.1%$1.53B$333.61M-27.6590Positive News
WVE
WAVE Life Sciences
4.5513 of 5 stars
$9.60
-3.3%
$20.27
+111.1%
+21.4%$1.53B$108.30M-10.67240Positive News

Related Companies and Tools


This page (NASDAQ:PRTA) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners